Relief Therapeutics’s Aviptadil gets FDA expanded access protocol for COVID-19

FDA signs off expanded access protocol to Relief Therapeutics’s (OTCPK:RLFTF) and its U.S. partner NeuroRx, for RLF-100 (aviptadil) in COVID-19 patients with respiratory failure.

The protocol makes treatment available to patients who have exhausted approved therapies and are not eligible for the current phase 2/3 trial of RLF-100 because of other medical conditions.

RLF-100 is a patented formulation of Aviptadil (synthetic human Vasoactive Intestinal Polypeptide VIP), which inhibits pro-inflammatory cytokines and protects alveolar type 2 cells in the lungs inhibiting pro-inflammatory cytokines, essential for oxygen exchange.

https://seekingalpha.com/news/3596771-relief-therapeuticss-aviptadil-gets-fda-expanded-access-protocol-for-covidminus-19